Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Background Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the pivotal Phase 2 study (NCT02760498). Here we rep...

Full description

Saved in:
Bibliographic Details
Main Authors: Dirk Schadendorf, Ralf Gutzmer, Thomas Eigentler, Israel Lowy, Vladimir Jankovic, Elizabeth Stankevich, Anna C Pavlick, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Nikhil I Khushalani, Brett G M Hughes, Lara A Dunn, Leonel Hernandez-Aya, Anne Lynn S Chang, Badri Modi, Axel Hauschild, Claas Ulrich, Brian Stein, Jessica L Geiger, Murad Alam, Emmanuel Okoye, Melissa Mathias, Jocelyn Booth, Siyu Li, Matthew G Fury, Alexander Guminski
Format: Article
Language:English
Published: BMJ Publishing Group 2020-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/1/e000775.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/1/e000775.full

Similar Items